SIOC 中文
CJOG
Adv search

Chinese Journal of Organic Chemistry >

2018 , Vol. 38 >Issue 6: 1549 - 1555

DOI: https://doi.org/10.6023/cjoc201801023

Notes

Synthesis and Anti-tumor Activities against HepG2 Cell in vitro of the Conjugates of Honokiol, Quercetin and Berberine

  • Liao Shili ,
  • Zhang Guogai ,
  • Cao Han ,
  • Chen Biying ,
  • Li Weimin ,
  • Wu Xia ,
  • Feng Yifan
Expand
  • a Central Laboratory, Guangdong Pharmaceutical University, Guangzhou 510000;
    b College of Chinese Materia Medica, Guangzhou University of Chinese Medicine, Guangzhou 510000

Received date: 2018-01-26

  Revised date: 2018-02-27

  Online published: 2018-03-08

Supported by

Project supported by the National Natural Science Foundation of China (Nos. 21275036, 81202429).

Fold

Abstract

Berberine, honokiol, quercetin are the lead compounds with outstanding anti-tumor activities. Three novel products were synthesized from honokiol, quercetin and berberine. The structures of the products were firstly confirmed by 1H NMR, 13C NMR, 2D NMR, HRMS, IR and UV. All products were evaluated for their anti-tumor activities against HepG2 cell in vitro and the results showed that the inhibitory effects of two compounds on HepG2 cell were far superior to honokiol and berberine hydrochloride, and the anti-tumor activities were similar to the reference drug cisplatin. It means that compounds 1 and 2 are expected to be the potential anti-tumor drugs.

Key words： berberine; honokiol; quercetin; anti-tumor activity

Cite this article

Liao Shili , Zhang Guogai , Cao Han , Chen Biying , Li Weimin , Wu Xia , Feng Yifan . Synthesis and Anti-tumor Activities against HepG2 Cell in vitro of the Conjugates of Honokiol, Quercetin and Berberine[J]. Chinese Journal of Organic Chemistry, 2018 , 38(6) : 1549 -1555 . DOI: 10.6023/cjoc201801023

References

[1] Zhang, S. L.; Chang, J. J.; Damu, G.; Fang, B.; Zhou, X. D.; Geng, R. X.; Zhou, C. H. Bioorg.Med.Chem.Lett. 2013, 23, 1008.
[2] Lin, C. F.; Hung, C. F.; Aljuffali, I. A.; Huang, Y. L.; Liao, W. C.; Fang, J. Y. Pharm.Res. 2016, 33, 2152.
[3] Hu, Y.; Davies, G. E. Fitoterapia 2010, 81, 358.
[4] Wang, X. H.; Duan, X. M.; Yang, G. L.; Zhang, X. Y.; Deng, L. Y.; Zheng, H.; Deng, C. Y.; Wen, J. L.; Wang, N. Peng, C.; Zhao, X.; Wei, Y. Q.; Chen, L. J. Plos One 2011, 6, e18490.
[5] Chiang, J.; Shen, Y. C.; Wang, Y. H.; Hou, Y. C.; Chen, C. C.; Liso, J. F.; Y, M. C.; Juan, C. W.; Liou, K. T. Eur.J.Pharmacol. 2009, 610, 119.
[6] Mendoza, E. E.; Burd, R. Mini-Rev. Med. Chem. 2011, 11, 1216.
[7] Patil, J. B.; Kim, J.; Jayaprakasha, G. K. Eur.J.Pharmacol. 2010, 645, 70.
[8] Zhou, B.; Li, H. Y.; Xing, C. Y.; Ye, H. G.; Feng, J. H.; Wu, J. B.; Lu, Z. Q.; Fang, J.; Gao, S. M. Biochem.Pharmacol. 2017, 128, 12.
[9] Fang, J. Y.; Huang, T. H.; Hung, C. F.; Huang, Y. L.; Aljuffali, I. A.; Liao, W. C.; Lin, C. F. Eur.J.Pharm.Sci. 2018, 114, 189.
[10] Garelnabi, M.; Mahini, H.; Wilson, T. J.Int.Soc.Sport.Nutr. 2014, 11, 22.
[11] Enkhtaivan, G.; Muthuraman, P.; Kim D. H.; Mistry, B. Bioorg.Med.Chem. 2017, 25, 5185.
[12] Mistry, B.; Patel, R. V.; Keum, Y. S.; Kim D. H. J.Saudi Chem. Soc. 2017, 21, 210.
[13] Ma, L.; Chen, J. Y.; Wang, X. W.; Liang, X. L. J.Med.Chem. 2011, 54, 6469.
[14] Lin, C. F. Int.J.Pharm. 2013, 445, 153.
[15] Mattarei, A.; Biasutto, L.; Rastrelli, F.; Garbisa, S.; Marotta, E. Molecules 2010, 15, 4722.
[16] Zhou, Z. H.; Fang, Z.; Jin, H.; Chen, Y. Synthesis 2010, 23, 3980.
[17] Cao, H; Liao, S. L; Zhong, W. J.; Xiao, X. R.; Zhu, J. C. Molecules 2017, 22, 1752.
[18] Cao, Y. B.; Sun, Q.; Jin, J.; Li, X. M. CN 104119330, 2014[Abstr. Chem. 2014, 161, 698825].
[19] Nechepurenko, I. V.; Komarova, N. I.; Vasil'ev, V. G.; Salakhutdinov, N. F. Chem.Nat.Compd. 2013, 48, 1047.
[20] Zhang, L. M.S. Thesis, Guangzhou University of Chinese Medicine, Guangzhou, 2015(in Chinese). (张磊, 硕士论文, 广州中医药大学, 广州, 2015.)

Options
Outlines

/

〈 〉